Latest Animal Health News

Page 3 of 4
Neurizon Therapeutics reported a $16.6 million loss for FY2025 amid significant progress in its lead neurodegenerative therapy NUZ-001, including regulatory milestones and a global licensing deal. The company is poised to enter a pivotal ALS clinical trial pending FDA clearance.
Ada Torres
Ada Torres
26 Aug 2025
Apiam Animal Health has entered a Process Deed granting Adamantem exclusivity to pursue a $0.88 per share acquisition proposal. The Independent Board Committee signals intent to recommend the deal, pending due diligence and shareholder approval.
Ada Torres
Ada Torres
25 Aug 2025
Apiam Animal Health has received a non-binding indicative proposal from Adamantem Capital Management to acquire the company at $0.88 per share, sparking a potential shift in ownership for the veterinary services leader.
Ada Torres
Ada Torres
18 Aug 2025
Vitrafy Life Sciences reported a $32.7 million loss for FY25, driven by investments in its next-generation cryopreservation platform following a $35 million IPO and a $4.8 million government grant. The company is progressing commercialization efforts with key partnerships in human and animal health.
Ada Torres
Ada Torres
5 Aug 2025
Neurizon Therapeutics has made significant strides in developing its lead ALS drug candidate NUZ-001, unveiling a new liquid formulation and submitting a key regulatory response to the FDA. Clinical and preclinical data bolster hopes for broader neurodegenerative applications.
Ada Torres
Ada Torres
30 July 2025
Vitrafy Life Sciences reported robust progress in Q4 FY2025, advancing its cryopreservation technology and commercial partnerships while preparing for a pivotal product launch in FY2026.
Ada Torres
Ada Torres
30 July 2025
Zoono Group Limited reports strong progress in its shelf-life extension technology with 45 active trials worldwide and anticipates UK revenue by Q2 FY26 following successful supermarket partnerships.
Ada Torres
Ada Torres
29 July 2025
IDT Australia has signed a memorandum with NASDAQ-listed Gelteq to establish a dedicated gel-based product manufacturing facility, marking a strategic expansion in pharmaceutical delivery technologies.
Victor Sage
Victor Sage
17 July 2025
Neurizon Therapeutics has inked a pivotal global licensing deal with Elanco Animal Health, unlocking critical intellectual property and data to accelerate the development and commercialisation of its lead drug candidate NUZ-001 for neurodegenerative diseases including ALS.
Ada Torres
Ada Torres
2 July 2025
Paradigm Biopharmaceuticals has acquired Proteobioactives, securing global rights to an oral combination therapy targeting early-stage osteoarthritis in humans and animals, complementing its injectable PPS phase 3 program.
Ada Torres
Ada Torres
26 June 2025
Apiam Animal Health announces the departure of CEO Chris Richards after nine years, appointing Bruce Dixon as interim managing director during the search for a permanent replacement.
Ada Torres
Ada Torres
5 June 2025
Avecho Biotechnology has received $1.66 million from the Australian Government’s R&D Tax Incentive, reinforcing its commitment to a pivotal Phase III trial for its CBD-based insomnia treatment and accelerating its commercial ambitions.
Ada Torres
Ada Torres
28 May 2025